All Stories

  1. The GALENOS approach to triangulating evidence: a structured approach for integrating information from human and animal studies
  2. The effect of heat exposure on mood disorders and psychosis: Protocol for a living systematic review of human and non-human studies (Preprint)
  3. Pro-dopaminergic pharmacological interventions for anhedonia in depression: a living systematic review and network meta-analysis of human and animal studies
  4. Developing treatments for cerebral small vessel disease: a scoping review of licensed interventions for potential repurposing
  5. A How-to Guide for Research Improvement within Research-Performing Institutions
  6. Mechanisms through which exercise reduces symptom severity and/or functional impairment in posttraumatic stress disorder (PTSD): Protocol for a living systematic review of human and non-human studies
  7. Building a synthesis-ready research ecosystem: fostering collaboration and open science to accelerate biomedical translation
  8. The therapeutic potential of exercise in post-traumatic stress disorder and its underlying mechanisms: A living systematic review of human and non-human studies
  9. Mechanisms through which exercise reduces symptom severity and/or functional impairment in posttraumatic stress disorder (PTSD): Protocol for a living systematic review of human and non-human studies
  10. Muscarinic receptor agonists and positive allosteric modulators in animal models of psychosis: protocol for a systematic review and meta-analysis
  11. Testing the usefulness of a quality system in preclinical research
  12. Triangulating evidence from the GALENOS living systematic review on trace amine-associated receptor 1 (TAAR1) agonists in psychosis
  13. Developing treatments for cerebral small vessel disease: a scoping review of licensed interventions for potential repurposing
  14. Safety and efficacy of memantine and trazodone versus placebo for motor neuron disease (MND SMART): stage two interim analysis from the first cycle of a phase 3, multiarm, multistage, randomised, adaptive platform trial
  15. A Systematic Online Living Evidence Summary of experimental Alzheimer’s disease research
  16. Strategy for developing data standards in support of automation of Systematic Reviews
  17. Analysis of animal-to-human translation shows that only 5% of animal-tested therapeutic interventions obtain regulatory approval for human applications
  18. Trace amine-associated receptor 1 (TAAR1) agonism for psychosis: a living systematic review and meta-analysis of human and non-human data
  19. Understanding the provenance and quality of methods is essential for responsible reuse of FAIR data
  20. Genetically modified animals as models of neurodevelopmental conditions: A review of systematic review reporting quality
  21. Prevention of infections and fever to improve outcome in older patients with acute stroke (PRECIOUS): a randomised, open, phase III, multifactorial, clinical trial with blinded outcome assessment
  22. Evaluating artificial intelligence software for delineating hemorrhage extent on CT brain imaging in stroke
  23. Genetically-modified animals as models of neurodevelopmental conditions: a review of systematic review reporting quality
  24. Mechanisms through which exercise reduces symptom severity and/or functional impairment in posttraumatic stress disorder (PTSD): Protocol for a living systematic review of human and non-human studies
  25. Pro-dopaminergic pharmacological interventions for anhedonia in depression: protocol for a living systematic review of human and non-human studies
  26. From data deluge to publomics: How AI can transform animal research
  27. Blood biomarker changes following therapeutic hypothermia in ischemic stroke
  28. A Systematic Online Living Evidence Summary of experimental Alzheimer’s disease research
  29. The Automated Systematic Search Deduplicator (ASySD): a rapid, open-source, interoperable tool to remove duplicate citations in biomedical systematic reviews
  30. The UK Reproducibility Network: A progress report
  31. Trace amine-associated receptor 1 (TAAR1) agonists for psychosis: protocol for a living systematic review and meta-analysis of human and non-human studies.
  32. New living evidence resource of human and non-human studies for early intervention and research prioritisation in anxiety, depression and psychosis
  33. Identifying a research agenda for postgraduate taught education in the UK: lessons from a machine learning facilitated systematic scoping review
  34. Accuracy of artificial intelligence software for CT angiography in stroke
  35. Systematic online living evidence summaries: emerging tools to accelerate evidence synthesis
  36. Designing, conducting, and reporting reproducible animal experiments
  37. Advanced methods and implementations for the meta-analyses of animal models: Current practices and future recommendations
  38. Screening for in vitro systematic reviews: a comparison of screening methods and training of a machine learning classifier
  39. EFFECTS OF GALACTO-OLIGOSACCHARIDE PREBIOTICS IN THE FLINDERS SENSITIVE LINE RAT MODEL OF DEPRESSION ON BEHAVIOURAL OUTCOMES
  40. Frequency and Phenotype Associations of Rare Variants in 5 Monogenic Cerebral Small Vessel Disease Genes in 200,000 UK Biobank Participants
  41. PICO entity extraction for preclinical animal literature
  42. The EQIPD framework for rigor in the design, conduct, analysis and documentation of animal experiments
  43. Screening for in vitro systematic reviews: a comparison of screening methods and training of a machine learning classifier
  44. Systematic Online Living Evidence Summaries: emerging tools to accelerate evidence synthesis
  45. Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease
  46. Meta-analysis on reporting practices as a source of heterogeneity in in vitro cancer research
  47. Effectiveness of biomaterial-based combination strategies for spinal cord repair – a systematic review and meta-analysis of preclinical literature
  48. Improving the reproducibility and integrity of research: what can different stakeholders contribute?
  49. A Systematic Approach to Identify Neuroprotective Interventions for Motor Neuron Disease
  50. MDAR (Material, Design, Analysis Reporting): A Modular Framework for Transparent Reporting in the Life Sciences
  51. What has preclinical systematic review ever done for us?
  52. The reproducibility debate is an opportunity, not a crisis
  53. Improving research quality: the view from the UK Reproducibility Network institutional leads for research improvement
  54. From grassroots to global: A blueprint for building a reproducibility network
  55. Risk of bias assessment in preclinical literature using natural language processing
  56. Using median survival in meta-analysis of experimental time-to-event data
  57. PICO Entity Extraction For Preclinical Animal Literature
  58. Meta-analysis on reporting practices as a source of heterogeneity in in vitro cancer research
  59. Technological advances in preclinical meta-research
  60. Building a Systematic Online Living Evidence Summary of COVID-19 Research
  61. Red blood cell transfusion in animal models of acute brain injuries: a systematic review protocol
  62. Risk of Bias Assessment in Preclinical Literature using Natural Language Processing
  63. Introduction to the EQIPD quality system
  64. Meta-analysis of variation suggests that embracing variability improves both replicability and generalizability in preclinical research
  65. Epidemiology and reporting characteristics of preclinical systematic reviews
  66. The Automated Systematic Search Deduplicator (ASySD): a rapid, open-source, interoperable tool to remove duplicate citations in biomedical systematic reviews
  67. The MDAR (Materials Design Analysis Reporting) Framework for transparent reporting in the life sciences
  68. Regulatory delays in a multinational clinical stroke trial
  69. Systematic review and meta-analysis of cannabinoids, cannabis-based medicines, and endocannabinoid system modulators tested for antinociceptive effects in animal models of injury-related or pathological persistent pain
  70. Development and uptake of an online systematic review platform: the early years of the CAMARADES Systematic Review Facility (SyRF)
  71. Results of a randomised controlled trial comparing two different incentives to improve survey response rates
  72. Using Median Survival in Meta-analysis of Experimental Time-to-event Data
  73. Protocol for an analysis of in vivo reporting standards by journal, institution and funder
  74. Comparison of commonly used methods in random effects meta-analysis: application to preclinical data in drug discovery research
  75. Can harmonisation of outcomes bridge the translation gap for pre-clinical research? A systematic review of outcomes measured in mouse models of type 2 diabetes
  76. Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data
  77. Feasibility of reporting results of large randomised controlled trials to participants: experience from the Fluoxetine Or Control Under Supervision (FOCUS) trial
  78. Effects of dietary fat manipulation on cognition in mice and rats: protocol for a systematic review and meta-analysisEffects of dietary fat manipulation on cognition in mice and rats: protocol for a systematic review and meta-analysis
  79. Red Blood Cell Transfusion in Animal Models of Acute Brain Injuries: A Systematic Review Protocol
  80. Embrace heterogeneity to improve reproducibility: A perspective from meta-analysis of variation in preclinical research
  81. The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days
  82. Identifying and understanding factors that affect the translation of therapies from the laboratory to patients: a study protocol
  83. The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days
  84. A Systematic Review and Meta-Analysis of Hypothermia in Experimental Traumatic Brain Injury: Why Have Promising Animal Studies Not Been Replicated in Pragmatic Clinical Trials?
  85. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study
  86. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research
  87. Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0
  88. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research
  89. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research*
  90. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research
  91. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research
  92. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research
  93. Identifying and understanding factors that affect the translation of therapies from the laboratory to patients: a study protocol
  94. Real-world Independent Testing of e-ASPECTS Software (RITeS): statistical analysis plan
  95. Systematic review of guidelines for internal validity in the design, conduct and analysis of preclinical biomedical experiments involving laboratory animals
  96. FAIR SCI Ahead: The Evolution of the Open Data Commons for Pre-Clinical Spinal Cord Injury Research
  97. UK consensus on pre-clinical vascular cognitive impairment functional outcomes assessment: Questionnaire and workshop proceedings
  98. Introducing our series: research synthesis and meta-research in biology
  99. Framework for advancing rigorous research
  100. Meta-analysis of targeted temperature management in animal models of cardiac arrest
  101. Research Culture and Reproducibility
  102. Ischaemic stroke
  103. Compressive Pressure Versus Time in Cauda Equina Syndrome
  104. The ARRIVE guidelines 2019: updated guidelines for reporting animal research
  105. Reporting animal research: Explanation and Elaboration for the ARRIVE guidelines 2019
  106. Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial
  107. Extending thrombolysis to 4·5–9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data
  108. A randomised controlled trial of an Intervention to Improve Compliance with the ARRIVE guidelines (IICARus)
  109. Outcome heterogeneity and bias in acute experimental spinal cord injury
  110. Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial
  111. Animal models of chemotherapy-induced peripheral neuropathy: A machine-assisted systematic review and meta-analysis
  112. Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke
  113. Administration of galacto-oligosaccharide prebiotics in the Flinders Sensitive Line animal model of depression
  114. Protocol for a systematic review and meta-analysis of data from preclinical studies employing forced swimming test: an update
  115. Towards minimum reporting standards for life scientists
  116. Therapeutic hypothermia for acute ischaemic stroke. Results of a European multicentre, randomised, phase III clinical trial
  117. A European initiative to unclog pipeline for new medicines
  118. The development and evaluation of an online application to assist in the extraction of data from graphs for use in systematic reviews
  119. Reader response: Evaluating depression and suicidality in tetrabenazine users with Huntington disease
  120. Did a change in Nature journals’ editorial policy for life sciences research improve reporting?
  121. Warlow's Stroke
  122. The development and evaluation of an online application to assist in the extraction of data from graphs for use in systematic reviews
  123. Machine learning algorithms for systematic review: reducing workload in a preclinical review of animal studies and reducing human screening error
  124. Identifying stroke therapeutics from preclinical models: A protocol for a novel application of network meta-analysis
  125. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial
  126. Design of Meta-Analysis Studies
  127. Targeting mitochondrial dysfunction in amyotrophic lateral sclerosis: a systematic review and meta-analysis
  128. Reproducibility and Rigor in Animal-Based Research
  129. The development and evaluation of an online application to assist in the extraction of data from graphs for use in systematic reviews
  130. Potentially serious incidental findings on brain and body magnetic resonance imaging of apparently asymptomatic adults: systematic review and meta-analysis
  131. Protocol for a systematic review of guidelines for rigour in the design, conduct and analysis of biomedical experiments involving laboratory animals
  132. The reproducibility opportunity
  133. NXY-059, a Failed Stroke Neuroprotectant, Offers No Protection to Stem Cell-Derived Human Neurons
  134. A randomised controlled trial of an Intervention to Improve Compliance with the ARRIVE guidelines (IICARus)
  135. PRECIOUS: PREvention of Complications to Improve OUtcome in elderly patients with acute Stroke. Rationale and design of a randomised, open, phase III, clinical trial with blinded outcome assessment
  136. Small vessels, dementia and chronic diseases – molecular mechanisms and pathophysiology
  137. Effect size and statistical power in the rodent fear conditioning literature – A systematic review
  138. Animal models of chemotherapy-induced peripheral neuropathy: a machine-assisted systematic review and meta-analysis A comprehensive summary of the field to inform robust experimental design
  139. Automation of citation screening in pre-clinical systematic reviews
  140. The REstart or STop Antithrombotics Randomised Trial (RESTART) after stroke due to intracerebral haemorrhage: study protocol for a randomised controlled trial
  141. Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial
  142. The use of text-mining and machine learning algorithms in systematic reviews: reducing workload in preclinical biomedical sciences and reducing human screening error
  143. A systematic review and meta-analysis of topoisomerase inhibition in pre-clinical glioma models
  144. Estimating the statistical performance of different approaches to meta-analysis of data from animal studies in identifying the impact of aspects of study design
  145. Facilitating healthcare decisions by assessing the certainty in the evidence from preclinical animal studies
  146. Learning lessons from MVA85A, a failed booster vaccine for BCG
  147. Transparency in the reporting of in vivo pre-clinical pain research: The relevance and implications of the ARRIVE (Animal Research: Reporting In Vivo Experiments) guidelines
  148. Correction: D-galactose-induced brain ageing model: A systematic review and meta-analysis on cognitive outcomes and oxidative stress indices
  149. Statistical analysis plan for the EuroHYP-1 trial: European multicentre, randomised, phase III clinical trial of the therapeutic hypothermia plus best medical treatment versus best medical treatment alone for acute ischaemic stroke
  150. Identification and characterization of outcome measures reported in animal models of epilepsy: Protocol for a systematic review of the literature-A TASK2 report of the AES/ILAE Translational Task Force of the ILAE
  151. Living systematic reviews: 2. Combining human and machine effort
  152. Living systematic reviews: 3. Statistical methods for updating meta-analyses
  153. Living systematic reviews: 4. Living guideline recommendations
  154. Risk of bias reporting in the recent animal focal cerebral ischaemia literature
  155. Marine-derived n-3 fatty acids therapy for stroke
  156. The Experimental Design Assistant
  157. The Experimental Design Assistant
  158. Findings of a retrospective, controlled cohort study of the impact of a change in Nature journals' editorial policy for life sciences research on the completeness of reporting study design and execution
  159. Standardized mean differences cause funnel plot distortion in publication bias assessments
  160. Living systematic review: 1. Introduction—the why, what, when, and how
  161. D-galactose-induced brain ageing model: A systematic review and meta-analysis on cognitive outcomes and oxidative stress indices
  162. Development of a psychological intervention for fatigue after stroke
  163. The IMPROVE Guidelines (Ischaemia Models: Procedural Refinements Of in Vivo Experiments)
  164. Alpha Calcitonin Gene-Related Peptide Increases Cerebral Vessel Diameter in Animal Models of Subarachnoid Hemorrhage: A Systematic Review and Meta-analysis
  165. Increasing value and reducing waste in stroke research
  166. Conjugal amyotrophic lateral sclerosis: a case report from Scotland
  167. Effect size and statistical power in the rodent fear conditioning literature - a systematic review
  168. Evolution of ischemic damage and behavioural deficit over 6 months after MCAo in the rat: Selecting the optimal outcomes and statistical power for multi-centre preclinical trials
  169. No publication without confirmation
  170. Hypothermia revisited: Impact of ischaemic duration and between experiment variability
  171. Improving our understanding of thein vivomodelling of psychotic disorders: A protocol for a systematic review and meta‐analysis
  172. Protocol for a systematic review and meta-analysis of experimental models of amyotrophic lateral sclerosis
  173. Understanding in vivo modelling of depression in non-human animals: a systematic review protocol
  174. Protocols for laboratory research
  175. Evaluating mesenchymal stem cell therapy for sepsis with preclinical meta-analyses prior to initiating a first-in-human trial
  176. The Devil Is in the Details: Incomplete Reporting in Preclinical Animal Research
  177. Study protocol - A systematic review and meta-analysis of hypothermia in experimental traumatic brain injury: Why have promising animal studies not been replicated in pragmatic clinical trials?
  178. Multicenter Evaluation of Geometric Accuracy of MRI Protocols Used in Experimental Stroke
  179. Systematic Review and Meta-Analysis of the Efficacy of Interleukin-1 Receptor Antagonist in Animal Models of Stroke: an Update
  180. Protocol for a systematic review of effect sizes and statistical power in the rodent fear conditioning literature
  181. The Efficacy of Trastuzumab in Animal Models of Breast Cancer: A Systematic Review and Meta-Analysis
  182. From a mouse: systematic analysis reveals limitations of experiments testing interventions in Alzheimer's disease mouse models
  183. A proposed framework for the systematic review and integrated assessment (SYRINA) of endocrine disrupting chemicals
  184. Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets
  185. Olfactory Ensheathing Cell Transplantation in Experimental Spinal Cord Injury: Effect size and Reporting Bias of 62 Experimental Treatments: A Systematic Review and Meta-Analysis
  186. SWIFT-Review: a text-mining workbench for systematic review
  187. Protocol for a retrospective, controlled cohort study of the impact of a change in Nature journals’ editorial policy for life sciences research on the completeness of reporting study design and execution
  188. Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF
  189. Cardiac Stem Cell Treatment in Myocardial InfarctionNovelty and Significance
  190. Corrigendum to ‘Meta-analysis of data from animal studies: A practical guide’
  191. How to Avoid Bumping into the Translational Roadblock
  192. AVERT 2 (a very early rehabilitation trial, a very effective reproductive trigger): retrospective observational analysis of the number of babies born to trial staff
  193. Effect of alteplase on the CT hyperdense artery sign and outcome after ischemic stroke
  194. Correction: Risk of Bias in Reports of In Vivo Research: A Focus for Improvement
  195. Informatics: Make sense of health data
  196. How individual participant data meta-analyses have influenced trial design, conduct, and analysis
  197. Translational failure of anti-inflammatory compounds for myocardial infarction: a meta-analysis of large animal models
  198. Risk of Bias in Reports of In Vivo Research: A Focus for Improvement
  199. The Clots in Legs Or sTockings after Stroke (CLOTS) 3 trial: a randomised controlled trial to determine whether or not intermittent pneumatic compression reduces the risk of post-stroke deep vein thrombosis and to estimate its cost-effectiveness
  200. Consent for Brain Tissue Donation after Intracerebral Haemorrhage: A Community-Based Study
  201. Exploring threats to generalisability in a large international rehabilitation trial (AVERT)
  202. Interventions for post-stroke fatigue
  203. Efficacy and safety of very early mobilisation within 24 h of stroke onset (AVERT): a randomised controlled trial
  204. Effect of Endothelin Receptor Antagonists on Clinically Relevant Outcomes after Experimental Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis
  205. Prof Benchie and Dr Athena-A modern tragedy…
  206. Increasing value and reducing waste in animal models of rheumatological disease
  207. Drug Repurposing: A Systematic Approach to Evaluate Candidate Oral Neuroprotective Interventions for Secondary Progressive Multiple Sclerosis
  208. Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): a randomised trial
  209. Experimental design and reporting standards for improving the internal validity of pre-clinical studies in the field of pain: Consensus of the IMI-Europain consortium
  210. Uptake of systematic reviews and meta-analyses based on individual participant data in clinical practice guidelines: descriptive study
  211. Magnetic Resonance Imaging in Experimental Stroke and Comparison With Histology
  212. Model of Understanding Fatigue After Stroke
  213. Influence of Intracerebral Hemorrhage Location on Incidence, Characteristics, and Outcome
  214. A systematic review and meta‐analysis of gene therapy in animal models of cerebral glioma: why did promise not translate to human therapy?
  215. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis
  216. Effect of intermittent pneumatic compression on disability, living circumstances, quality of life, and hospital costs after stroke: secondary analyses from CLOTS 3, a randomised trial
  217. Similar Effect of Autologous and Allogeneic Cell Therapy for Ischemic Heart Disease: Systematic Review and Meta-Analysis of Large Animal Studies
  218. Efficacy of Antidepressants in Animal Models of Ischemic Stroke: A Systematic Review and Meta-Analysis
  219. Preclinical research: Design animal studies better
  220. Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embol...
  221. EuroHYP-1: European Multicenter, Randomized, Phase III Clinical Trial of Therapeutic Hypothermia plus Best Medical Treatment vs. Best Medical Treatment Alone for Acute Ischemic Stroke
  222. End-of-life decisions in patients with severe acute brain injury
  223. Psychological Associations of Poststroke Fatigue: A Systematic Review and Meta-Analysis
  224. Using Animal Models to Understand Cancer Pain in Humans
  225. Outcome After Conservative Management or Intervention for Unruptured Brain Arteriovenous Malformations
  226. Clopidogrel Plus Aspirin Versus Warfarin in Patients With Stroke and Aortic Arch Plaques
  227. Research: increasing value, reducing waste – Authors' reply
  228. Systematic Reviews and Meta-Analysis of Preclinical Studies: Why Perform Them and How to Appraise Them Critically
  229. Exercise Reduces Infarct Volume and Facilitates Neurobehavioral Recovery
  230. Therapeutic Hypothermia and the Risk of Infection
  231. A (mini) pill for stroke?
  232. Some Salt with Your Statin, Professor?
  233. Hypothermia Protects Human Neurons
  234. Systematic Review and Meta-Analysis of Interventions Tested in Animal Models of Lacunar Stroke
  235. Meta-analysis of data from animal studies: A practical guide
  236. Increasing value and reducing waste in research design, conduct, and analysis
  237. Increasing value and reducing waste in biomedical research regulation and management
  238. Effect and Reporting Bias of RhoA/ROCK-Blockade Intervention on Locomotor Recovery After Spinal Cord Injury
  239. Biomedical research: increasing value, reducing waste
  240. Efficacy and safety of mesenchymal stromal cells in preclinical models of acute lung injury: a systematic review protocol
  241. Stem Cell Transplantation in Traumatic Spinal Cord Injury: A Systematic Review and Meta-Analysis of Animal Studies
  242. Edoxaban versus Warfarin in Patients with Atrial Fibrillation
  243. Bringing rigour to translational medicine
  244. Edaravone Improves Functional and Structural Outcomes in Animal Models of Focal Cerebral Ischemia: A Systematic Review
  245. Meta-Analysis of Pre-Clinical Studies of Early Decompression in Acute Spinal Cord Injury: A Battle of Time and Pressure
  246. Systematic Review and Meta-Analysis of Therapeutic Hypothermia in Animal Models of Spinal Cord Injury
  247. Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial
  248. Evaluation of Excess Significance Bias in Animal Studies of Neurological Diseases
  249. Hypertension and Experimental Stroke Therapies
  250. Animal models of bone cancer pain: Systematic review and meta-analyses
  251. Systematic review and stratified meta-analysis of the efficacy of RhoA and Rho kinase inhibitors in animal models of ischaemic stroke
  252. Prevalence and natural history of pain in adults with multiple sclerosis: Systematic review and meta-analysis
  253. A Concerted Appeal for International Cooperation in Preclinical Stroke Research
  254. Evidence-based Translational Medicine
  255. Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted?
  256. Role of multidetector computed tomography in the diagnosis and management of patients attending the rapid access chest pain clinic, The Scottish computed tomography of the heart (SCOT-HEART) trial: study protocol for randomized controlled trial
  257. A call for transparent reporting to optimize the predictive value of preclinical research
  258. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial
  259. The Benefit of Hypothermia in Experimental Ischemic Stroke is Not Affected by Pethidine
  260. Improving the Efficiency of the Development of Drugs for Stroke
  261. Translational Research
  262. Stem Cell-Based Therapy for Experimental Stroke: A Systematic Review and Meta-Analysis
  263. Voltage-gated potassium channel antibody-related encephalopathy: a case which may extend the documented phenotype of this condition
  264. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial
  265. Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial
  266. Pharmacologic Reduction of Angiographic Vasospasm in Experimental Subarachnoid Hemorrhage: Systematic Review and Meta-Analysis
  267. Vorapaxar in the Secondary Prevention of Atherothrombotic Events
  268. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF
  269. Untreated clinical course of cerebral cavernous malformations: a prospective, population-based cohort study
  270. Evaluation of Combination Therapy in Animal Models of Cerebral Ischemia
  271. Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited
  272. The timing, extent, progression and regression of deep vein thrombosis in immobile stroke patients: observational data from the CLOTS multicenter randomized trials
  273. Preclinical studies of human disease: Time to take methodological quality seriously
  274. Why animal research needs to improve
  275. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
  276. Sodium and chloride channelopathies with myositis: Coincidence or connection?
  277. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial
  278. Dopamine agonists in animal models of Parkinson’s disease: A systematic review and meta-analysis
  279. Not Tonight, Darling, I Might Get a Headache
  280. Systematic Survey of the Design, Statistical Analysis, and Reporting of Studies Published in the 2008 Volume of the Journal of Cerebral Blood Flow and Metabolism
  281. Treatment of intracerebral hemorrhage in animal models: Meta-analysis
  282. Systematic Survey of the Design, Statistical Analysis, and Reporting of Studies Published in the 2008 Volume of theJournal of Cerebral Blood Flow and Metabolism
  283. Animal models of neurological disease: are there any babies in the bathwater?
  284. Hypothermia for Stroke: Call to Action 2010
  285. Preclinical Drug Evaluation for Combination Therapy in Acute Stroke Using Systematic Review, Meta-Analysis, and Subsequent Experimental Testing
  286. B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial
  287. Improving the translational hit of experimental treatments in multiple sclerosis
  288. Factors Affecting the Apparent Efficacy and Safety of Tissue Plasminogen Activator in Thrombotic Occlusion Models of Stroke: Systematic Review and Meta-Analysis
  289. Different Strokes for Different Folks: The Rich Diversity of Animal Models of Focal Cerebral Ischemia
  290. Comment on "Detection of an Infectious Retrovirus, XMRV, in Blood Cells of Patients with Chronic Fatigue Syndrome"
  291. Therapeutic Hypothermia for Acute Ischemic Stroke: Ready to Start Large Randomized Trials?
  292. Publication Bias in Reports of Animal Stroke Studies Leads to Major Overstatement of Efficacy
  293. Can Animal Models of Disease Reliably Inform Human Studies?
  294. How to Avoid Bumping into the Translational Roadblock
  295. A Systematic Review and Meta-Analysis of Erythropoietin in Experimental Stroke
  296. Emulating Multicentre Clinical Stroke Trials: A New Paradigm for Studying Novel Interventions in Experimental Models of Stroke
  297. Bacterial meningitis associated with a complex ischiorectal abscess
  298. Stroke research at a road block: the streets from adversity should be paved with meta-analysis and good laboratory practice
  299. Systematic Review and Stratified Meta-analysis of the Efficacy of Interleukin-1 Receptor Antagonist in Animal Models of Stroke
  300. Scope of Preclinical Testing Versus Quality Control Within Experiments
  301. Injury-induced mineralocorticoid receptor expression involves differential promoter usage: A novel role for the rat MRβ variant
  302. Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial
  303. Reprint: Good Laboratory Practice: Preventing Introduction of Bias at the Bench
  304. Stroke Therapy Academic Industry Roundtable (STAIR) Recommendations for Extended Window Acute Stroke Therapy Trials
  305. Surgical decompression for space-occupying cerebral infarction (the Hemicraniectomy After Middle Cerebral Artery infarction with Life-threatening Edema Trial [HAMLET]): a multicentre, open, randomised trial
  306. Mineralocorticoid receptor mRNA expression is increased in human hippocampus following brief cerebral ischaemia
  307. Update of the Stroke Therapy Academic Industry Roundtable Preclinical Recommendations
  308. REPRINT: Good Laboratory Practice: Preventing Introduction of Bias at the Bench
  309. Effect of hyperthermia and anoxia on glucocorticoid and mineralocorticoid receptor expression in neonatal rat hippocampus
  310. Rationale and Design of a Randomized, Double-Blind, Parallel-Group Study of Terutroban 30 mg/day versus Aspirin 100 mg/day in Stroke Patients: The Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients wi...
  311. General anaesthesia versus local anaesthesia for carotid surgery (GALA): a multicentre, randomised controlled trial
  312. The Future of Restorative Neurosciences in Stroke: Driving the Translational Research Pipeline From Basic Science to Rehabilitation of People After Stroke
  313. What is the translational efficacy of chemotherapeutic drug research in neuro-oncology? A systematic review and meta-analysis of the efficacy of BCNU and CCNU in animal models of glioma
  314. Reprint: Good Laboratory Practice: Preventing Introduction of Bias at the Bench
  315. Secondary prevention of stroke – Authors' reply
  316. Good Laboratory Practice: Preventing Introduction of Bias at the Bench
  317. Evidence for the Efficacy of NXY-059 in Experimental Focal Cerebral Ischaemia Is Confounded by Study Quality
  318. Stroke
  319. Predicting outcome in hyper-acute stroke: validation of a prognostic model in the Third International Stroke Trial (IST3)
  320. Outcome after interventional or conservative management of unruptured brain arteriovenous malformations: a prospective, population-based cohort study
  321. Empirical Evidence of Bias in the Design of Experimental Stroke Studies: A Metaepidemiologic Approach
  322. A Systematic Review and Meta-Analysis of the Efficacy of Piracetam and Piracetam-Like Compounds in Experimental Stroke
  323. How can we improve the pre-clinical development of drugs for stroke?
  324. Vanishing diplopia: a problem case
  325. Hypothermia in animal models of acute ischaemic stroke: a systematic review and meta-analysis
  326. Forebrain mineralocorticoid receptor overexpression enhances memory, reduces anxiety and attenuates neuronal loss in cerebral ischaemia
  327. Systematic Review and Meta-Analysis of the Efficacy of Tirilazad in Experimental Stroke
  328. Comparison of treatment effects between animal experiments and clinical trials: systematic review
  329. Hemicraniectomy after middle cerebral artery infarction with life-threatening Edema trial (HAMLET). Protocol for a randomised controlled trial of decompressive surgery in space-occupying hemispheric infarction
  330. Aortic Arch Atheroma
  331. 1,026 Experimental treatments in acute stroke
  332. Greater Incidence of Both Fatal and Nonfatal Strokes in Disadvantaged Areas: The Northeast Melbourne Stroke Incidence Study
  333. Current Issues in the Treatment of Acute Posterior Circulation Stroke
  334. Epilepsy update
  335. Surveying the literature from animal experiments: Systematic review and meta-analysis are important contributions
  336. Neuro-oncology for non-oncologists
  337. Overexpression of the mineralocorticoid receptor protects against injury in PC12 cells
  338. Systematic Review and Metaanalysis of the Efficacy of FK506 in Experimental Stroke
  339. Gender and deprivation and rates of referral and thereby admission to a national neurorehabilitation service
  340. Systematic review and meta-analysis of the efficacy of melatonin in experimental stroke
  341. Results of a Multicentre, Randomised Controlled Trial of Intra-Arterial Urokinase in the Treatment of Acute Posterior Circulation Ischaemic Stroke
  342. MicroRNA – Taking Regulation of Protein Synthesis to Another Level
  343. Nicotinamide Attenuates Focal Ischemic Brain Injury: Meta-Analysis or Mechanism of Protection
  344. Atheroma of the aortic arch: an important and poorly recognised factor in the aetiology of stroke
  345. Pooling of Animal Experimental Data Reveals Influence of Study Design and Publication Bias
  346. Media Watch
  347. Atheroma of the aortic arch: the missing link in the secondary prevention of stroke?
  348. Inequalities in the incidence and management of, and outcome from, neurological diseases in older people
  349. Mineralocorticoid receptor expression and increased survival following neuronal injury
  350. Effect of deprivation on time to hospital in acute stroke
  351. Reduced NMDA-induced apoptosis in neurons lacking ataxia telangiectasia mutated protein
  352. PubMed: http://www.pubmed.org
  353. Effect of deprivation and gender on the incidence and management of acute brain disorders
  354. What's a good doctor and how do you make one?
  355. Nitric-oxide-synthase-mediated cyclic guanosine monophosphate production in neonatal rat cerebellar prisms is resistant to calcineurin inhibition
  356. Serum withdrawal causes apoptosis in SHSY 5Y cells
  357. Caspase 6 activity initiates caspase 3 activation in cerebellar granule cell apoptosis
  358. The effect of tumour associated epilepsy on performance/handicap scales used in cerebral glioma
  359. Ischaemic heart disease and cholesterol There's more to heart disease than cholesterol